Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

2. Heartland Financial USA, Inc.

22.4% sales growth and 7.54% return on equity

Heartland Financial USA, Inc., a multi-bank holding company, provides commercial, small business, and consumer banking services to individuals and businesses in the United States.

Heartland Financial USA, Inc.’s sales growth this year is expected to be 12.2% and a negative 0.5% for next year.

Year-on-year quarterly revenue growth grew by 10.1%, now sitting on 535.2M for the twelve trailing months.

Heartland Financial USA, Inc.’s sales growth for the next quarter is 22.4%. The company’s growth estimates for the current quarter and the next is 103.7% and 32.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.54%.

Volatility

Heartland Financial USA, Inc.’s last day, last week, and last month’s current volatility was 0.66%, 1.33%, and 1.31%, respectively.

Heartland Financial USA, Inc.’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.26% (day), 3.03% (last week), and 3.19% (last month), respectively.

Heartland Financial USA, Inc.’s Stock Yearly Top and Bottom Value

Heartland Financial USA, Inc.’s stock is valued at $50.01 at 02:22 EST, under its 52-week high of $54.04 and way above its 52-week low of $25.30.

Heartland Financial USA, Inc.’s Moving Average

Heartland Financial USA, Inc.’s worth is below its 50-day moving average of $50.50 and way higher than its 200-day moving average of $42.89.

3. Abbott Laboratories

55.7% sales growth and 13.91% return on equity

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide.

Abbott Laboratories’s sales growth this year is anticipated to be 21.9% and a negative 0.3% for next year.

Year-on-year quarterly revenue growth grew by 28.7%, now sitting on 34.61B for the twelve trailing months.

Abbott Laboratories’s sales growth for the next quarter is 55.7%. The company’s growth estimates for the ongoing quarter and the next is 95.4% and 121.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.91%.

Volatility

Abbott Laboratories’s last day, last week, and last month’s current volatility was 0.33%, 1.07%, and 0.96%, respectively.

Abbott Laboratories’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.35% (day), 1.58% (last week), and 1.82% (last month), respectively.

Abbott Laboratories’s Stock Yearly Top and Bottom Value

Abbott Laboratories’s stock is valued at $124.35 at 02:22 EST, under its 52-week high of $128.54 and way above its 52-week low of $81.05.

Abbott Laboratories’s Moving Average

Abbott Laboratories’s worth is higher than its 50-day moving average of $120.14 and way above its 200-day moving average of $112.93.

Previous days news about Abbott Laboratories

According to Business Insider on Saturday, 17 April, "Johnson & Johnson (before the market open) Abbott Laboratories (NYSE:ABT) (before the market open) Intuitive Surgical, Inc. (NASDAQ:ISRG) (after the close)"

According to MarketWatch on Tuesday, 20 April, "Shares of Abbott Laboratories were down 3.2% in premarket trading on Tuesday after the company beat earnings expectations during a quarter in which sales of its COVID-19 tests made up 20% of total revenue. "

According to Bloomberg Quint on Wednesday, 21 April, "Strong results from the company alongside medical devices heavyweights Abbott Laboratories and Edwards Lifesciences Corp. have signaled to investors that elective surgeries are returning more rapidly than expected as the U.S. economy reopens."

4. FleetCor Technologies, Inc.

21.6% sales growth and 19.93% return on equity

FLEETCOR Technologies, Inc. operates as a business payments company that simplifies the way businesses manage and pay expenses.

FleetCor Technologies, Inc.’s sales growth this year is expected to be 11.3% and 11.3% for next year.

Year-on-year quarterly revenue growth declined by 11.7%, now sitting on 2.39B for the twelve trailing months.

FleetCor Technologies, Inc.’s sales growth for the next quarter is 21.6%. The company’s growth estimates for the ongoing quarter and the next is a negative 9% and 28.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.93%.

Volatility

FleetCor Technologies, Inc.’s last day, last week, and last month’s current volatility was 0.08%, 0.45%, and 1.03%, respectively.

FleetCor Technologies, Inc.’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.68% (day), 1.42% (last week), and 1.93% (last month), respectively.

FleetCor Technologies, Inc.’s Stock Yearly Top and Bottom Value

FleetCor Technologies, Inc.’s stock is valued at $291.46 at 02:22 EST, below its 52-week high of $295.00 and way higher than its 52-week low of $203.18.

FleetCor Technologies, Inc.’s Moving Average

FleetCor Technologies, Inc.’s value is higher than its 50-day moving average of $281.68 and higher than its 200-day moving average of $265.54.

5. Afya

48.2% sales growth and 12.45% return on equity

Afya Limited, through its subsidiaries, operates as a medical education group in Brazil.

Afya’s sales growth this year is expected to be 37.8% and 22% for next year.

Year-on-year quarterly revenue growth grew by 56.3%, now sitting on 1.2B for the twelve trailing months.

Afya’s sales growth for the next quarter is 48.2%. The company’s growth estimates for the ongoing quarter and the next is 7.7% and negative -25%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.45%.

Volatility

Afya’s last day, last week, and last month’s current volatility was 2.12%, 3.16%, and 2.36%, respectively.

Afya’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.94% (day), 4.49% (last week), and 4.51% (last month), respectively.

Afya’s Stock Yearly Top and Bottom Value

Afya’s stock is valued at $22.49 at 02:22 EST, way under its 52-week high of $29.01 and way higher than its 52-week low of $16.20.

Afya’s Moving Average

Afya’s worth is above its 50-day moving average of $21.33 and under its 200-day moving average of $24.27.

6. Alexion Pharmaceuticals, Inc.

12.9% sales growth and 5.26% return on equity

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products.

Alexion Pharmaceuticals, Inc.’s sales growth this year is anticipated to be 8% and 7.9% for next year.

Year-on-year quarterly revenue growth grew by 15%, now sitting on 6.07B for the twelve trailing months.

Alexion Pharmaceuticals, Inc.’s sales growth for the next quarter is 12.9%. The company’s growth estimates for the current quarter and the next is a negative 1.9% and 4.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.26%.

Volatility

Alexion Pharmaceuticals, Inc.’s last day, last week, and last month’s current volatility was 3.90%, 1.44%, and 1.05%, respectively.

Alexion Pharmaceuticals, Inc.’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.65% (day), 1.00% (last week), and 1.14% (last month), respectively.

Alexion Pharmaceuticals, Inc.’s Stock Yearly Top and Bottom Value

Alexion Pharmaceuticals, Inc.’s stock is valued at $163.68 at 02:22 EST, under its 52-week high of $164.60 and way higher than its 52-week low of $94.82.

Alexion Pharmaceuticals, Inc.’s Moving Average

Alexion Pharmaceuticals, Inc.’s worth is higher than its 50-day moving average of $153.08 and way above its 200-day moving average of $142.40.

LEAVE A REPLY

Please enter your comment!
Please enter your name here